Compartilhar
Informação da revista
Vol. 46. Núm. S4.
HEMO 2024
Páginas S32-S33 (outubro 2024)
Vol. 46. Núm. S4.
HEMO 2024
Páginas S32-S33 (outubro 2024)
Acesso de texto completo
ENERGIZE: A GLOBAL PHASE 3 STUDY OF MITAPIVAT DEMONSTRATING EFFICACY AND SAFETY IN ADULTS WITH ALPHA- OR BETA-NON–TRANSFUSION-DEPENDENT THALASSEMIA
Visitas
373
AT Tahera, H Al-Samkarib, Y Aydinokc, M Besserd, G Lunae, S Gheuensf, A Glenthjg, AS Gohh, A Kattamisi, SR Loggettoj, KM Musallamk, P Ricchil, E Salido-Fiérrezm, S Shethn, V Viprakasito, MD Cappellinip, KH Kuoq
a Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
b Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, United States
c Department of Paediatric Haematology and Oncology, Ege University School of Medicine, Izmir, Turkey
d Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
e Centre de Référence Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l’Érythropoïèse, Hôpital Henri Mondor APHP, Paris, France
f Agios Pharmaceuticals, Inc., Cambridge, United States
g Department of Haematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
h Haematology Unit, Department of Medicine, Hospital Pulau Pinang, Penang, Malaysia
i Thalassemia Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece
j São Paulo Blood Bank - GSH Group, São Paulo, Brazil
k Center for Research on Rare Blood Disorders (CR-RBD), Burjeel Medical City, Abu Dhabi, UAE
l Unità Operativa Semplice Dipartimentale Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo, Nazionale, Cardarelli, Napoli, Italy
m Department of Haematology, Hospital Clínico Universitario Virgen de la Arrixaca-IMIB, Murcia, Spain
n Division of Hematology and Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, United States
o Department of Pediatrics & Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
p Department of Clinical Sciences and Community, University of Milan, Ca'Granda Foundation IRCCS Maggiore Policlinico Hospital, Milan, Italy
q Division of Hematology, University of Toronto, Toronto, Canada
Ver más
Este item recebeu
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S4

HEMO 2024

Mais dados
Background

In thalassemia, ATP production in erythroid cells is too low to meet the demand of oxidative stress and ensuing cellular damage; this leads to ineffective erythropoiesis (IE) and chronic hemolytic anemia. Guidelines for non–transfusion-dependent thalassemia (NTDT) recommend raising hemoglobin (Hb) by ≥1 g/dL to reduce morbidities from IE and anemia. No oral disease-modifying therapies are approved for the treatment of β-thalassemia, and no agents are approved for α-thalassemia. Mitapivat is a first-in-class, oral, activator of pyruvate kinase that increases ATP production. Mitapivat may reduce metabolic stress, addressing the underlying pathophysiology across the full range of thalassemias, with the potential to reduce complications and improve health-related quality of life (HRQoL).

Aims

To assess the efficacy and safety of mitapivat vs placebo (pbo) in adults with α- or β-NTDT in ENERGIZE (NCT04770753), a phase 3, double-blind, randomized, pbo-controlled, global trial.

Methods

Adults (≥18 years) with α- or β-NTDT and baseline (BL) Hb ≤10 g/dL were randomized 2:1 to mitapivat 100 mg twice daily or pbo for 24 weeks (wks). NTDT was defined as ≤5 red blood cell (RBC) units transfused 24 wks before randomization and no RBC transfusions ≤8 wks before informed consent or during screening. The primary endpoint was Hb response: ≥1.0 g/dL increase in average Hb concentration over Wks 12–24 compared with BL. Key secondary endpoints were changes from BL in average Hb concentration and Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT-Fatigue) score over Wks 12–24. Safety and markers of hemolysis and erythropoiesis were among the secondary endpoints.

Results

194 patients (pts) were randomized (mitapivat n = 130; pbo n = 64); 94.8% completed the 24-wk trial. Mean age was 41.2 years, mean BL Hb was 8.3 g/dL, 86.6% received no transfusions in the 24 wks before randomization, and 32.0% had α-NTDT. BL characteristics were similar between treatment arms. Mitapivat demonstrated statistically significant improvements vs pbo for Hb response (42.3% vs 1.6%, respectively; 2-sided p < 0.0001), and for changes from BL in Wks 12–24 average Hb (least-squares mean [LSM] difference (95% CI): 0.96 g/dL (0.78, 1.15); 2-sided p < 0.0001) and Wks 12–24 average FACIT-Fatigue score (LSM difference (95% CI): 3.40 (1.21, 5.59); 2-sided p < 0.0026). Results favored mitapivat across all prespecified subgroups. Improvements in several markers of hemolysis and erythropoiesis were also observed, consistent with the proposed mechanism of mitapivat. The proportion of pts with treatment-emergent adverse events (TEAEs) of any grade was similar across treatment arms (mitapivat 82.9%; pbo 79.4%). The most common TEAEs (≥10% of pts) with mitapivat were headache, initial insomnia, nausea, and upper respiratory tract infection. Among mitapivat-treated pts, 6.2% had serious TEAEs (none considered treatment related) and 3.1% had TEAEs leading to treatment discontinuation; none occurred with pbo.

Summary/Conclusion

Mitapivat significantly increased Hb and improved fatigue vs pbo; improvements were observed across all prespecified subgroups. Mitapivat was generally well tolerated with a low treatment discontinuation rate. These data are the first proof of efficacy of a disease-modifying therapy across the full range of NTDT (α- and β-thalassemia). Mitapivat may represent a new oral treatment option addressing both pathophysiology and HRQoL in thalassemia.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas